List of Excipients in Branded Drug INFUMORPH 200

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Hikma Pharmaceuticals USA Inc	INFUMORPH 200	morphine sulfate	0641-6039	SODIUM CHLORIDE
Hikma Pharmaceuticals USA Inc	INFUMORPH 200	morphine sulfate	0641-6039	SODIUM HYDROXIDE
Hikma Pharmaceuticals USA Inc	INFUMORPH 200	morphine sulfate	0641-6039	SULFURIC ACID
Hikma Pharmaceuticals USA Inc	INFUMORPH 200	morphine sulfate	0641-6039	WATER

INFUMORPH 200 Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 15, 2026

INFUMORPH 200 is a high-concentration, preservative-free morphine sulfate injection containing 200 mg in a 10 mL vial, equivalent to 20 mg/mL. Its commercial value is tied less to complex excipient intellectual property than to route-specific safety, concentration, sterility, pump compatibility, and supply reliability. The product is used for continuous microinfusion through implanted pumps in patients with severe chronic pain and is administered intrathecally or epidurally under specialized clinical supervision. [1]

The formulation uses a narrow excipient profile: sodium chloride and Water for Injection. That simplicity reduces formulation differentiation but creates opportunities in container closure, ready-to-use presentations, pump compatibility, manufacturing control, and portfolio extensions.

What is INFUMORPH 200 and how is it formulated?

INFUMORPH 200 is morphine sulfate injection, USP, at a concentration of 20 mg/mL.

Attribute	INFUMORPH 200
Active ingredient	Morphine sulfate
Strength	200 mg/10 mL
Concentration	20 mg/mL
Dosage form	Sterile injectable solution
Preservatives	None
Primary route	Intrathecal infusion
Secondary route	Epidural administration
Excipient	Sodium chloride
Diluent	Water for Injection
Product type	Prescription drug
Primary use	Continuous infusion for chronic intractable pain
Administration setting	Implanted infusion pump and specialist care

The label identifies sodium chloride as the tonicity-adjusting excipient. The formulation is acidic, with a labeled pH range of approximately 2.5 to 6.5. [1] The absence of antimicrobial preservatives is important because neuraxial administration imposes tighter safety expectations than conventional intravenous products.

Why does INFUMORPH 200 use a minimal excipient system?

The formulation is designed to minimize exposure to unnecessary excipients in the intrathecal and epidural spaces. A limited formulation can reduce risks associated with preservatives, antimicrobial agents, particulate contamination, and excipient-induced tissue irritation.

The strategy also supports manufacturing consistency. A two-component excipient system is easier to control than a formulation containing buffers, antioxidants, surfactants, or viscosity modifiers. The tradeoff is that the manufacturer must manage morphine degradation, container interaction, pH drift, sterility, and pump-reservoir stability through process controls and packaging selection rather than through a complex stabilizer system.

What excipients are protected by INFUMORPH 200?

No publicly established, commercially meaningful excipient patent position is apparent from the product’s core formulation. The formulation uses sodium chloride and Water for Injection, both established pharmaceutical ingredients with broad prior-art coverage and limited standalone exclusivity potential.

The relevant intellectual-property value is more likely to arise from:

• Concentration-specific formulation claims
• Preservative-free neuraxial compositions
• Stability in implantable pump reservoirs
• Container-closure systems
• Fill-finish processes
• Low-particulate manufacturing
• Compatibility with specific infusion devices
• Storage conditions and in-use dating
• Combination claims covering morphine and a pump or delivery system

A formulation patent would need to claim a non-obvious technical result, such as improved stability, reduced adsorption, reduced degradation, or validated compatibility with a defined pump system. Sodium chloride alone would not normally create a strong exclusivity position.

What formulation opportunities exist beyond the current excipient system?

Potential development paths include:

1. Stability-enhanced preservative-free formulations. A developer could evaluate pH control, oxygen control, container materials, and headspace management without adding excipients that are unsuitable for neuraxial delivery.

2. Pre-filled pump reservoirs. A sterile, ready-to-load reservoir could reduce preparation steps and dosing errors. Commercial value would depend on device compatibility and regulatory classification.

3. Extended-use presentations. A product designed for longer pump refill intervals could reduce procedure frequency, subject to validated chemical stability, sterility, and device requirements.

4. Lower-volume high-concentration products. A more concentrated product could extend pump duration but would require careful assessment of dose accuracy, local tolerability, and pump calibration.

5. Pediatric or low-dose presentations. Lower concentrations could improve dosing control in selected patients, although they would require separate clinical and labeling strategies.

6. Combination pump formulations. A formulation combining morphine with another analgesic could target patients requiring multimodal intrathecal therapy. Such products would face compatibility, stability, dosing, and clinical evidence barriers.

What is the FDA regulatory status of INFUMORPH 200?

INFUMORPH is an FDA-approved morphine sulfate injection product marketed for severe chronic pain requiring continuous intrathecal or epidural infusion. The FDA-approved labeling identifies the product as preservative-free and limits its use to controlled clinical settings because neuraxial morphine can cause serious respiratory depression, sedation, hypotension, urinary retention, and other opioid-related adverse reactions. [1]

The product’s route-specific labeling is commercially important. A conventional morphine sulfate injection approved for intravenous or intramuscular use is not automatically an equivalent substitute for an intrathecal product. Preservative content, concentration, sterility assurance, labeling, and route authorization affect whether a product can be used in an implanted pump.

Is INFUMORPH 200 a generic drug?

INFUMORPH 200 is an NDA product rather than a standard ANDA generic presentation. An ANDA applicant seeking approval of a directly substitutable product would need to address the applicable reference-listed-drug requirements, including pharmaceutical equivalence, route, strength, dosage form, labeling, and bioequivalence or other applicable requirements.

The absence of a conventional oral or injectable generic substitution pathway does not eliminate competition. Hospitals and pain specialists may use other morphine sulfate products under applicable clinical and institutional protocols, but route-specific suitability and preservative status can restrict substitution.

What is the Orange Book status of INFUMORPH 200?

The Orange Book is the controlling public source for determining listed patents, exclusivity, therapeutic equivalence codes, and reference-listed-drug status. [2] INFUMORPH is associated with NDA 019947 in FDA product records. A current Orange Book review should be used for the operative listing and any changes to patent or exclusivity status.

The product’s commercial protection does not appear to depend on a current, high-value patent covering the basic morphine sulfate and sodium chloride formulation. Its protection profile is more consistent with an established NDA product whose defensibility comes from regulatory complexity, specialized use, physician familiarity, controlled distribution, and manufacturing requirements.

When did INFUMORPH 200 lose conventional exclusivity?

INFUMORPH was approved decades ago, so any original new-drug exclusivity and ordinary small-molecule patent protection would have expired. The continuing business opportunity is therefore based on market access and product execution rather than remaining original-molecule exclusivity.

FDA exclusivity should be distinguished from product differentiation. An old NDA can retain commercial relevance even after statutory exclusivity has ended if few competitors offer the same concentration, preservative-free status, route labeling, packaging, and supply reliability.

Which companies are challenging INFUMORPH 200?

Publicly visible competition is likely to come from manufacturers of morphine sulfate injection and specialized pain-management products rather than from a large branded litigation campaign. A complete Paragraph IV assessment requires current FDA Orange Book and court-docket data.

A Paragraph IV challenge would be commercially relevant only if an applicant sought approval of a product that relied on INFUMORPH as the reference product and alleged that listed patents were invalid, unenforceable, or not infringed. If no active listed patent covers the relevant product, an applicant may not need a Paragraph IV certification for the core formulation.

Potential competitors include:

• Generic injectable morphine manufacturers
• Hospital-supply companies
• Compounding pharmacies operating within applicable law
• Specialty manufacturers of intrathecal analgesic products
• Device companies offering integrated pump and drug-delivery systems

What patent litigation affects INFUMORPH 200?

No major, widely reported patent litigation directly defining the current market position of INFUMORPH 200 is apparent from the product’s long commercial history and established formulation. The principal legal risks are more likely to involve manufacturing, labeling, device compatibility, supply arrangements, or product liability than a live composition-of-matter dispute.

A diligence review should separate four categories:

Legal category	Relevance to INFUMORPH 200
Composition patents	Low for old morphine sulfate formulation
Excipient patents	Low for sodium chloride and Water for Injection
Method-of-use patents	Possible for specific pain protocols or patient populations
Device and pump patents	Potentially relevant to integrated delivery systems
Manufacturing patents	Potentially relevant to sterile fill-finish and stability
Regulatory litigation	Possible in approval, labeling, or market-access disputes

How strong is the patent estate for INFUMORPH 200?

The core patent estate appears weak as a standalone barrier to entry. Morphine sulfate is an established active ingredient, and the basic preservative-free aqueous formulation has limited prospects for durable composition patent protection.

The commercial moat is stronger in non-patent areas:

Protection factor	Relative strength
Active ingredient exclusivity	Low
Basic excipient composition	Low
FDA approval and labeling	Moderate
Neuraxial-use requirements	Moderate to high
Sterile manufacturing capability	Moderate
Pump compatibility data	Moderate
Prescriber and hospital familiarity	Moderate
Supply reliability	High when competitors are limited
Device integration	Potentially high
Trade secrets and process know-how	Moderate

The strongest investment case is therefore operational. A competitor may be able to reproduce the active ingredient and excipient profile but still face difficulty validating a sterile, preservative-free, high-concentration product for implanted pump use.

What manufacturing and IP barriers affect commercial entry?

Manufacturing barriers are more material than excipient patent barriers.

Sterility and particulate control

Intrathecal products require rigorous control of sterility, endotoxins, visible and subvisible particulates, container integrity, and aseptic processing. Failures can trigger recalls, warning letters, or supply interruption.

Concentration accuracy

At 20 mg/mL, fill-volume and assay controls are commercially important. Small volumetric errors can affect total pump dose over an extended infusion period.

Container compatibility

The manufacturer must evaluate adsorption, extractables and leachables, stopper compatibility, glass or polymer interaction, and stability over the labeled shelf life. These data can create practical differentiation even without broad patent protection.

Pump-reservoir compatibility

The drug must be evaluated with the intended implanted pump and refill procedures. Compatibility may depend on concentration, temperature, reservoir materials, flow rate, storage time, and handling. Device-specific data can create a commercial barrier where formal patent protection is limited.

Supply-chain qualification

Hospitals may be reluctant to substitute a product used in implantable systems without validated protocols and pharmacy approval. Reliable availability, standardized packaging, and predictable lot release can support contracting advantages.

What commercial opportunities exist for INFUMORPH 200?

The highest-value opportunities are concentrated in specialty distribution, hospital contracting, and product extensions.

Hospital and specialty pharmacy contracting

INFUMORPH 200 can be positioned as a standardized, ready-to-use neuraxial morphine product for pain centers, anesthesiology departments, neurosurgical programs, and specialty pharmacies. Contracting value increases when the product reduces pharmacy preparation and supports consistent pump-refill procedures.

Supply-resilience positioning

A manufacturer can compete on continuity of supply, dual-site manufacturing, inventory depth, and transparent shortage communication. For implanted-pump patients, switching products can impose clinical and operational costs. Reliability can therefore support premium or preferred-vendor positioning.

Device partnerships

Partnerships with implantable pump manufacturers could create integrated commercial offerings. Potential structures include co-marketing, compatibility validation, bundled hospital contracts, or device-specific distribution. Any arrangement would need to comply with FDA promotion rules, anti-kickback restrictions, purchasing controls, and applicable device-drug requirements.

New presentations

Commercially attractive extensions include:

• Smaller vials for dose-specific use
• Unit-of-use packaging
• Pre-filled syringes for controlled preparation environments
• Pump-compatible reservoirs
• Lower-concentration versions
• Higher-concentration versions supported by clinical and compatibility data

Each extension would require a regulatory strategy. A new presentation may be eligible for an NDA supplement, a new drug application, or another FDA pathway depending on the changes and supporting data.

How does INFUMORPH 200 compare with conventional morphine injections?

Factor	INFUMORPH 200	Conventional morphine injection
Primary use	Continuous intrathecal or epidural infusion	Usually systemic analgesia
Concentration	20 mg/mL	Varies
Preservatives	Preservative-free	Depends on product
Delivery	Implanted pump or neuraxial administration	IV, IM, or subcutaneous use depending on label
Main differentiation	Route, concentration, and pump use	Broad hospital analgesia
Substitution risk	Requires route-specific review	Not automatically interchangeable
Commercial buyer	Pain center, specialty pharmacy, hospital	Broad hospital and retail channels
Key barrier	Sterility, compatibility, specialized labeling	Generic price competition

The products may contain the same active ingredient but occupy different regulatory and clinical markets. Concentration alone does not establish equivalence.

What generic launch scenarios exist for INFUMORPH 200?

Scenario 1: Direct preservative-free generic

A competitor develops a 20 mg/mL preservative-free morphine sulfate injection with matching route and dosage-form characteristics. This would create the most direct price pressure. The main barriers would be FDA approval, sterile manufacturing, compatibility evidence, and hospital adoption.

Scenario 2: Alternative concentration

A competitor launches a different strength that can be used in selected pump protocols. This may take share without directly replicating the 20 mg/mL presentation, although dosing and pump-specific requirements could limit substitution.

Scenario 3: Hospital-prepared compounded product

Hospitals or pharmacies prepare a preservative-free morphine solution under applicable compounding rules. This can create local price competition but may not provide the same national supply, standardized labeling, or manufacturer-backed stability package.

Scenario 4: Integrated drug-device offering

A pump manufacturer or specialty pharmaceutical company markets a validated product linked to a particular infusion system. This could shift competition from drug price to total treatment workflow and device economics.

What biosimilar risk applies to INFUMORPH 200?

Biosimilar risk is not applicable. Morphine sulfate is a chemically synthesized small molecule, not a biologic. The relevant competitive threats are ANDA generics, alternative morphine presentations, compounded products, and drug-device systems.

What revenue exposure does INFUMORPH 200 create?

Public revenue attributable specifically to INFUMORPH 200 is generally not disclosed separately in corporate filings. Commercial exposure should be modeled through market variables rather than reported product revenue.

Revenue driver	Impact
Number of implanted-pump patients	Determines recurring demand
Refill frequency	Drives unit consumption
Product concentration	Affects vial utilization
Hospital contract status	Determines price and volume
Generic entry	Creates unit-price pressure
Supply shortages	Can shift market share rapidly
Pump compatibility	Affects switching costs
Specialty distribution access	Determines patient reach
New presentations	Expands account coverage

A practical forecast should separate volume growth from price. Demand is likely to be relatively specialized and recurring, while price sensitivity can increase sharply after a directly substitutable generic enters the market.

Key Takeaways

• INFUMORPH 200 contains morphine sulfate 200 mg in 10 mL, or 20 mg/mL.
• Its excipient system is minimal: sodium chloride and Water for Injection.
• The formulation does not present a strong standalone excipient patent barrier.
• Commercial defensibility comes from preservative-free neuraxial use, sterile manufacturing, pump compatibility, labeling, and supply reliability.
• Conventional morphine injections are not automatically substitutes for INFUMORPH 200.
• Biosimilar risk does not apply because morphine sulfate is a small molecule.
• The most credible growth opportunities are ready-to-use packaging, pump-reservoir products, device partnerships, alternate concentrations, and specialty hospital contracting.
• Generic entry would likely pressure price, but clinical protocols and validated pump compatibility could slow conversion.
• Current Orange Book listings and litigation dockets should control any final patent or Paragraph IV determination.

FAQs

Is INFUMORPH 200 preservative-free?

Yes. INFUMORPH 200 is labeled as a preservative-free morphine sulfate injection intended for intrathecal or epidural use. [1]

Can injectable morphine generics be used in an implanted pump?

Not automatically. The product must be evaluated for route authorization, preservative status, concentration, sterility, stability, labeling, and pump compatibility.

Does INFUMORPH 200 have an excipient patent?

The basic sodium chloride and Water for Injection formulation does not create an apparent strong standalone excipient patent position. Any relevant protection would more likely involve stability, packaging, manufacturing, or pump compatibility.

Is INFUMORPH 200 interchangeable with oral morphine?

No. Oral morphine and intrathecal morphine have different routes, dosing requirements, pharmacology, and safety risks. Substitution requires clinical judgment and applicable product labeling.

Could a pre-filled INFUMORPH 200 syringe be commercially attractive?

Yes. A pre-filled presentation could reduce pharmacy preparation, improve workflow standardization, and support specialty distribution. It would require appropriate container-closure, sterility, stability, device-compatibility, and FDA regulatory support.

References

1. U.S. Food and Drug Administration. (n.d.). INFUMORPH- morphine sulfate injection, solution: Prescribing information. FDA-approved labeling.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (n.d.). Small business assistance: Frequently asked questions on the Orange Book and generic drug approvals. FDA.

4. United States Pharmacopeial Convention. (n.d.). United States Pharmacopeia and National Formulary. USP.